Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dipak R Patel

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Translational Research : the Journal of Laboratory and Clinical Medicine|May 18, 2011
Linking interferon regulatory factors to the pathogenesis of human lupusDipak R Patel
Arthritis Research & Therapy|February 5, 2013
Dissecting complex epigenetic alterations in human lupusDipak R Patel, Bruce C Richardson
Current Opinion in Rheumatology|May 7, 2010
Epigenetic mechanisms in lupusDipak R Patel, Bruce C Richardson
Nature Reviews. Rheumatology|January 15, 2014
Epigenetics in 2013. DNA methylation and miRNA: key roles in systemic autoimmunityBruce C Richardson, Dipak R Patel
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2004
Altered Th1 cell differentiation programming by CIITA deficiencyDipak R Patel, Mark H Kaplan, Cheong-Hee Chang
Arthritis and Rheumatism|May 3, 2012
Protein kinase Cδ oxidation contributes to ERK inactivation in lupus T cellsGabriela J Gorelik, Sushma Yarlagadda, Dipak R Patel, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 15, 2022
PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab togetherC Steven Ernest, Jenny Y Chien, Dipak R Patel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 24, 2002
Aberrant expression of Fas ligand in mice deficient for the MHC class II transactivatorTania S Gourley, Dipak R Patel, Kevin Nickerson, et al.
Infectious Diseases and Therapy|August 10, 2021
A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2Ramesh Nathan, Imad Shawa, Inmaculada De La Torre, et al.
Infectious Diseases and Therapy|September 4, 2024
Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19Dipak R Patel, Lisa Macpherson, Martin Bohm, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Translational Research : the Journal of Laboratory and Clinical Medicine|May 18, 2011
Linking interferon regulatory factors to the pathogenesis of human lupusDipak R Patel
Arthritis Research & Therapy|February 5, 2013
Dissecting complex epigenetic alterations in human lupusDipak R Patel, Bruce C Richardson
Current Opinion in Rheumatology|May 7, 2010
Epigenetic mechanisms in lupusDipak R Patel, Bruce C Richardson
Nature Reviews. Rheumatology|January 15, 2014
Epigenetics in 2013. DNA methylation and miRNA: key roles in systemic autoimmunityBruce C Richardson, Dipak R Patel
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2004
Altered Th1 cell differentiation programming by CIITA deficiencyDipak R Patel, Mark H Kaplan, Cheong-Hee Chang
Arthritis and Rheumatism|May 3, 2012
Protein kinase Cδ oxidation contributes to ERK inactivation in lupus T cellsGabriela J Gorelik, Sushma Yarlagadda, Dipak R Patel, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 15, 2022
PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab togetherC Steven Ernest, Jenny Y Chien, Dipak R Patel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 24, 2002
Aberrant expression of Fas ligand in mice deficient for the MHC class II transactivatorTania S Gourley, Dipak R Patel, Kevin Nickerson, et al.
Infectious Diseases and Therapy|August 10, 2021
A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2Ramesh Nathan, Imad Shawa, Inmaculada De La Torre, et al.
Infectious Diseases and Therapy|September 4, 2024
Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19Dipak R Patel, Lisa Macpherson, Martin Bohm, et al.
Pageof 3